Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The human immunodeficiency viruses (hiv) clinical trials market size has experienced robust expansion over recent years. It is projected to expand from $1.94 billion in 2025 to $2.11 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. This historical growth is largely due to a significant global HIV disease burden, the expanding scope of antiretroviral drug research, increased public and private funding directed towards HIV studies, advancements in clinical research infrastructure, and supportive regulatory frameworks for HIV drug development.
The human immunodeficiency viruses (hiv) clinical trials market size is anticipated to experience substantial growth over the upcoming years, projected to reach $2.97 billion by 2030, at a compound annual growth rate (CAGR) of 8.9%. This expansion during the forecast period is driven by the increasing development of curative and preventive hiv therapies, the rising adoption of adaptive trial designs, the expansion of vaccine-focused hiv trials, the growing application of AI in clinical research, and a heightened focus on long-term safety and efficacy outcomes. Major trends expected in this period encompass the increasing adoption of decentralized clinical trial models, the rising use of digital patient recruitment tools, an intensifying focus on long-acting hiv therapies in trials, the broader integration of real-world evidence, and the enhanced use of data analytics in trial management.
Get A Free Sample Report With In-Depth Market Insights:
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Growth Momentum: What Factors Are Shaping Demand?
The anticipated expansion of the human immunodeficiency virus (HIV) clinical trials market is set to be driven by the rising frequency of human immunodeficiency virus (HIV) infections. Human immunodeficiency virus (HIV) infections are defined as a state where the HIV virus compromises and debilitates the immune system, making individuals more vulnerable to illnesses and potentially progressing to AIDS. A primary factor contributing to the rise in HIV infections is insufficient awareness regarding its transmission, which leads to high-risk activities and belated diagnostic testing, thereby accelerating the virus’s dissemination. These human immunodeficiency virus (HIV) clinical trials aim to aid individuals with HIV infections by evaluating novel medications, vaccinations, and therapeutic approaches to enhance prevention, ensure more efficient viral management, and ultimately curb disease advancement and spread. For example, data released in August 2024 by the US-based government agency, the Minority HIV/AIDS Fund (MHAF), indicated that approximately 39.9 million individuals globally were living with HIV in 2023, comprising 38.6 million adults and 1.4 million children, a figure comparable to prior years. Consequently, the escalating occurrence of human immunodeficiency virus (HIV) infections is a key impetus for the expansion of the human immunodeficiency virus (HIV) clinical trials market.
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Segment Landscape And Growth Outlook
The human immunodeficiency viruses (hiv) clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical
2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations
5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies
2) By Phase II: Dose-Finding Studies, Efficacy Studies
3) By Phase III: Pivotal Trials, Comparative Efficacy Studies
4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies
5) By Preclinical: In Vitro Studies, Animal Studies
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Trends Redefining Industry Growth
Major enterprises active within the human immunodeficiency virus (HIV) clinical trials sector are concentrating on creating novel remedies, such as HIV prevention injections, to boost treatment effectiveness and decrease transmission rates. An HIV prevention injection refers to a long-duration injectable medicine administered at intervals to avert HIV infection among individuals at elevated risk, by obstructing the virus from establishing itself in the body. For instance, in August 2025, Gilead Sciences Inc., a pharmaceutical firm based in the US, secured approval from the European Union for Yeytuo (lenacapavir) for HIV treatment. This twice-yearly injectable HIV prevention therapy demonstrates substantial effectiveness, achieving nearly 100% in clinical trials, thereby considerably lowering the chances of sexually transmitted HIV-1 infection. Its extended-release dosage enhances patient compliance and convenience when compared to daily oral PrEP, thereby addressing a significant void in HIV prevention efforts. This solution is intended for adults and adolescents at increased susceptibility, with the objective of expanding availability and contributing to a reduction in new global HIV infections as part of comprehensive prevention frameworks.
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio
View The Full Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report:
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency viruses (hiv) clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
